3578 T3D3536 Telithromycin Telithromycin is an exogenous solid compound with the formula C43H65N5O10. Telithromycin belongs to the carbohydrates and carbohydrate conjugates, a subclass of organooxygen compounds within the organic compounds. With an average molecular weight of 812.00 g/mol, Telithromycin is a heavy molecule. It is found in healthcare, pharmaceuticals, and veterinary products, specifically among antibiotics and macrolides, lincosamides, and streptogramins. Recorded exposure routes include oral and inhalation. This compound acts by binding to domains II and V of 23S rRNA of the 50S ribosomal subunit. By binding at domain II, telithromycin retains activity against gram-positive cocci, such as Streptococcus pneumoniae, in the presence of resistance mediated by methylases (erm genes) that alter the domain V binding site. Additionally, telithromycin may inhibit the assembly of nascent ribosomal units. Its recorded protein targets include Cytochrome P450 3A7 (CYP3A7), Cytochrome P450 1A2 (CYP1A2), Cytochrome P450 3A4 (CYP3A4), Cytochrome P450 3A5 (CYP3A5), and one other protein. Telithromycin is used to treat mild to moderate respiratory infections by interfering with bacterial protein synthesis and blocking further peptide elongation. 191114-48-4 5462516 C43H65N5O10 811.473140 White powder. 176-188°C 300 mg/L Absolute bioavailability is approximately 57%. Maximal concentrations are reached 0.5 - 4 hours following oral administration. Food intake does not affected absorption. Telithromycin acts by binding to domains II and V of 23S rRNA of the 50S ribosomal subunit. By binding at domain II, telithromycin retains activity against gram-positive cocci (e.g., <i>Streptococcus pneumoniae</i>) in the presence of resistance mediated by methylases (erm genes) that alter the domain V binding site of telithromycin. Telithromycin may also inhibit the assembly of nascent ribosomal units. Compared to erythromycin A, telithromycin binds to the 23S rRNA with 10 times greater affinity in erythromycin-susceptible organisms and 25 times greater affinity in macrolide-resistant strains. This increased binding affinity may be conferred by the C11-12 carbamate side chain of telithromycin. The side chain appears to maintain binding at domain II in the presence of resistance mediated by alterations in domain V. Hepatic - estimated 50% metabolized by CYP3A4 and 50% metabolized independent of cytochrome P450 Route of Elimination: The systemically available telithromycin is eliminated by multiple pathways as follows: 7% of the dose is excreted unchanged in feces by biliary and/or intestinal secretion; 13% of the dose is excreted unchanged in urine by renal excretion; and 37% of the dose is metabolized by the liver. Half Life: Main elimination half-life is 2-3 hours; terminal elimination half-life is 10 hours LD50>2000 mg/kg (PO in rats). No indication of carcinogenicity to humans (not listed by IARC). For the treatment of <i>Pneumococcal</i> infection, acute sinusitis, acute bacterial tonsillitis, acute bronchitis and bronchiolitis, lower respiratory tract infection and lobar (pneumococcal) pneumonia. Most common side-effects are gastrointestinal, including diarrhea, nausea, abdominal pain and vomiting. Headache and disturbances in taste also occur. Less common side-effects include palpitations, blurred vision and rashes. [Wikipedia] 2009-07-30T17:59:10Z 2026-05-14T16:54:40Z Telithromycin C12009 Telithromycin DB00976 true CC[C@@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCN3C=NC(=C3)C3=CC=CN=C3)C(=O)O[C@@]12C)OC C43H65N5O10 InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33+,36-,37-,38-,40+,42-,43+/m1/s1 LJVAJPDWBABPEJ-RMNISARHSA-N 812.0037 811.473143325 Exogenous Solid 3 HMDB15111 CHEMBL1136 26329513 <p>Suhas Sohani, Mandar Deodhar, Nishant Patel, Manish Patel, Mahesh Davadra, Vinodhamar Kansal, &#8220;Process for the Preparation of Telithromycin.&#8221; U.S. Patent US20070260066, issued November 08, 2007.</p> CHEM002532 DTXSID3046455 NS00002486 (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-10-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-4-ethyl-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-{4-[4-(pyridin-3-yl)-1H-imidazol-1-yl]butyl}-tetradecahydro-1H-oxacyclotetradeca[4,3-d][1,3]oxazole-2,6,8,14-tetrone 171.85000000000002 214.68349999999995 89.26623157269239 11 11 1 8.838963958185415 7.654524260411075 1 5 4.00 -4.46 2.83e-02 g/l Organic compounds Organic oxygen compounds Organooxygen compounds Carbohydrates and carbohydrate conjugates 1020 CED0005545 LJVAJPDWBABPEJ-RMNISARHSA-N 20000000008000000000000008000000000000400300000000000044000200020000200000000400000028000000000000060100008000000000000000000000008000000004009000000008208000010001000000001080022000000000000100000000400000041042440000000209040000800028000000001000001002480000008000000000000040009004800000000040000000004000202008000400100004010000040c00000000000000002b0000000110200000010100000000000020801100000410000000000000000000000000020200000101000000000000000080002040000000010040000000000000000100000000000000 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 776t3gAAAAAQAAAAAwAAAAAAAAA6AAAAPgAAAIABBgBgAAAAAQMGAGAAAAAC AgYgNAAAAAIBBAgAKAAAAAMCBgAoAAAAAwQIACgAAAADAgYgNAAAAAIBBAYA YAAAAAEDBgAoAAAAAwQIACgAAAADAgYgNAAAAAIBBAYAYAAAAAEDBiA0AAAA AQEECAAgAAAAAgYgNAAAAAIBBAgAIAAAAAIGIDQAAAACAQQGAGAAAAABAwYA YAAAAAICBiA0AAAAAQEEBiA0AAAAAQEECABgAAAAAQEHACAAAAADBgBgAAAA AQMGAGAAAAABAwYgJAAAAAEEBgBgAAAAAQMGAGAAAAACAgYgNAAAAAEBBAYA YAAAAAEDBgAoAAAAAwQIACgAAAADAgYgNAAAAAIBBAYAYAAAAAEDBiA0AAAA AQEEBwAoAAAAAwMGAGAAAAACAgYAYAAAAAICBgBgAAAAAgIGAGAAAAACAgdA KAAAAAMDBkBoAAAAAwMBB0AoAAAAAwMGQCgAAAADBAZAaAAAAAMDAQZAKAAA AAMEBkBoAAAAAwMBBkBoAAAAAwMBBkBoAAAAAwMBB0AoAAAAAwMGQGgAAAAD AwEGACgAAAADBAgAKAAAAAMCCAAoAAAAAwIGICQAAAABBAYAYAAAAAEDCAAg AAAAAgYAYAAAAAEDCwABAAECAAIDAAMEIAQFKAIEBgAGBwAGCAAICQgCCAoA CgsACgwADA0ADQ4ADg8ADxAAEBEAEBIAEhMAExQAFBUAExYAFhcAFhgADBkA GRoAGRsAGxwAHB0AHB4AHh8IAh4gACAhACAiACIjACMkACQlACUmACYnACco ACgpaAwpKmgMKitoDCssaAwrLSAtLmgMLi9oDC8waAwwMWgMMTJoDCMzIDM0 KAIzNSA1NgA2NwAZOAA4OQA2AgAUDgA2IgAsKGgMMi1oDEIFAAAADgI2IiAe HBsZDAoIBgQDBg8QEhMUDgUpKCwrKgYuLzAxMi0FMyMiNjUXBAAAAAAAAAAW 2026-09-19T04:00:48Z